TSPYL6 (TSPY-like 6) is a chr2-associated protein with histone binding capacity that functions as a transcriptional regulator of cytochrome P450 genes. While primarily characterized as part of the TSPYL family of CYP gene regulators 1, TSPYL6 specifically has been identified as a cancer-testis antigen with potential immunotherapeutic relevance in growth hormone-secreting pituitary adenomas and non-functioning adenomas 2. Functionally, TSPYL6 likely operates through chr2 binding mechanisms to modulate gene expression, consistent with its nuclear localization and histone-binding properties. Clinically, TSPYL6 genetic variants show significant disease associations: polymorphisms correlate with altered breast cancer susceptibility in Han Chinese populations, with specific SNPs (rs11896604, rs843706, rs11125529, rs843711) demonstrating protective or risk-increasing effects 3. Additionally, TSPYL6 SNPs are associated with increased ischemic stroke risk, potentially through telomere length regulation as a marker of biological aging 4. TSPYL6 has also been identified as a novel candidate gene in primary ovarian insufficiency 5. These findings suggest TSPYL6 functions as a multi-system regulator with implications for cancer predisposition, vascular disease, and reproductive health.